Key result
Despite a marked reduction in tumor size following R-CHOP chemotherapy, the patient with primary cardiac lymphoma died of multiple organ failure secondary to MRSA sepsis 17 days later.
Case Report (n=1)
No
Early implementation of chemotherapy with rituximab should be considered as a therapeutic diagnostic option in select patients with suspected primary cardiac lymphoma.
Answers are grounded in this paper and cite their sources.
Highlights fatal sepsis risk despite tumor response in primary cardiac lymphoma; hypothesis-generating for early rituximab use in select cases.
A 79-year-old man was admitted because of complete heart block. Echocardiograms showed an abnormal mass adjacent to the sinus of Valsalva. Subsequent surgical resection was not successful. Despite chemotherapy, the patient died from multiple organ failure. It is important to recognize that approximately 80% of cases of cardiac lymphoma are diffuse large B-cell lymphoma, which is the only malignant neoplasm that may respond well to chemotherapy with rituximab. In order to save patients' lives, the early implementation of chemotherapy with rituximab is critical and should be considered as a therapeutic diagnostic option in select patients.
No takes yet. Share an insight, caveat, or question.
Ito et al. (2018) conducted a case report in Primary Cardiac Lymphoma (n=1). Rituximab-based chemotherapy (R-CHOP) was evaluated. Despite a marked reduction in tumor size following R-CHOP chemotherapy, the patient with primary cardiac lymphoma died of multiple organ failure secondary to MRSA sepsis 17 days later.
Synapse has enriched 10 related papers. Consider them for comparative context: